<div id="readability-page-1"><p>TD Cowen analyst Tyler Van Buren has maintained their bullish  stance on <span>SMMT</span> stock, giving a Buy rating on May 4.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Tyler Van Buren has given his Buy rating due to a combination of factors, including confidence in Summit Therapeutics’ long-term revenue outlook despite recent adjustments. Following the Q1 report, he modestly raised operating expense projections for 2026 and beyond, but importantly left both annual and peak sales expectations intact, signaling sustained conviction in the company’s growth potential.</p> <p>He also appears encouraged by management’s post-earnings commentary, particularly around the HARMONi-3 progression-free survival interim update, which supports the underlying clinical and commercial thesis. Overall, the combination of stable revenue assumptions, only incremental cost adjustments, and continued positive signals from the pipeline underpins his view that the risk/reward profile remains attractive for investors at current levels.</p> <p>In another report released on May 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.</p> </div>

SMMT

SBIO

IBBQ

LABU

<p>TD Cowen analyst Tyler Van Buren has reiterated a Buy rating on Summit Therapeutics (SMMT) due to a stable long-term sales outlook and an attractive risk/reward profile. Despite raising future operating expense projections, he maintained sales expectations, reflecting confidence in the company's growth potential. Encouraged by management's commentary and clinical updates, Van Buren believes the stock remains a solid investment. H.C. Wainwright also supports this view with a Buy rating and a $23.00 price target.</p>

Tip Ranks

Summit Therapeutics

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Toronto Dominion Bank

Tyler Van Buren Reiterates Buy on Summit Therapeutics, Citing Stable Long-Term Sales Outlook and Attractive Risk/Reward Despite Higher Future OpEx